A strategy for risk mitigation of antibodies with fast clearance

Cited by (245)

Items 101–200 of 245

1. A Two-in-One antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions
   Chingwei V. Lee, Patrick S. Koenig, Germaine Fuh · 2014 · mAbs
2. Immune repertoire mining for rapid affinity optimization of mouse monoclonal antibodies
   Yi-Chun Hsiao, Yonglei Shang, Danielle M. DiCara, Angie Yee, Joyce J Lai, Si Hyun Kim, Diego A. Ellerman, Racquel T. Corpuz, Yongmei Chen, Sharmila Rajan et al. · 2019 · mAbs
3. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues
   Nazlı Eda Kaleli, Murat Karadag, Sibel Kalyoncu · 2019 · Proteins Structure Function and Bioinformatics
4. Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies
   Marissa L. Mock, Alex W. Jacobitz, CHRISTOPHER JAMES LANGMEAD, Athena M. Sudom, Daniel Yoo, Sara C. Humphreys, Mai Alday, Larysa Alekseychyk, Nicolas Angell, Vivian Bi et al. · 2023 · mAbs
5. Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6
   Emma von Witting, Javad Garousi, Sarah Lindbo, Anzhelika Vorobyeva, Mohamed Altai, Maryam Oroujeni, Bogdan Mitran, Anna Orlova, Sophia Hober, Толмачев Владимир Максимилианович · 2019 · European Journal of Pharmaceutics and Biopharmaceutics
6. In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation
   Li, Bing, Fouts, Ashley E, Stengel, Katharina, Luan, Peng, Dillon, Michael, Liang, Wei-Ching, Feierbach, Becket, Kelley, Robert F, Hötzel, Isidro · 2014 · mAbs
7. Nonspecificity in a nonimmune human scFv repertoire
   Ryan L. Kelly, Jessie Zhao, Doris Le, Karl Dane Wittrup · 2017 · mAbs
8. Lab-in-the-loop therapeutic antibody design with deep learning
   Nathan C. Frey, I. Hötzel, S. Stanton, Ryan L Kelly, R. Alberstein, Emily K. Makowski, Karolis Martinkus, Daniel Berenberg, J. Bevers, Tyler Bryson et al. · 2025 · bioRxiv
9. Use of Generic LC–MS/MS Assays to Characterize Atypical PK Profile of A Biotherapeutic Monoclonal Antibody
   Wai Siang Law, Jean‐Christophe Genin, Christian Miess, Gwenola Tréton, Andrew Paul Warren, Peter M. Lloyd, Sherri Dudal, Carsten Krantz · 2014 · Bioanalysis
10. A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
    Christopher O. Barnes, Till Schoofs, Priyanthi N.P. Gnanapragasam, Jovana Golijanin, Kathryn E. Huey‐Tubman, Henning Gruell, Philipp Schommers, Nina Suh-Toma, Yu Erica Lee, Julio C. C. Lorenzi et al. · 2022 · Science Advances
11. Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data
    Xiangdan Wang, Patrick McKay, Liliana T. Yee, George Dutina, Philip E. Hass, Ihsan Nijem, David Allison, Kyra J. Cowan, Kevin Lin, Valerie E. Quarmby et al. · 2016 · mAbs
12. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
    Emily K. Makowski, Hongwei Chen, Matthew A. Lambert, Eric M. Bennett, Nicole S. Eschmann, Yulei Zhang, Jennifer M. Zupancic, Alec A. Desai, Matthew D. Smith, Wenjia Lou et al. · 2022 · mAbs
13. Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies
    Sue Townsend, Brian J. Fennell, James R. Apgar, Matthew A. Lambert, Barry McDonnell, Joanne Grant, Jason M. Wade, Edward Franklin, Niall Foy, Deirdre Ní Shúilleabháin et al. · 2015 · Proceedings of the National Academy of Sciences
14. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport
    Qing Li, Jason B. White, Norman C. Peterson, Keith W. Rickert, Christopher Lloyd, Kevin L. Allen, Kim Rosenthal, Xizhe Gao, Herren Wu, William F. Dall’Acqua et al. · 2018 · Journal of Controlled Release
15. i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists
    Matthew G. Romei, Brandon C. Leonard, Zachary Katz, Daniel Le, Yanli Yang, Eric S. Day, Christopher W. Koo, Preeti Apurve Sharma, Jack J. Bevers, Ingrid Kim et al. · 2024 · Nature Communications
16. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment
    Christopher Negron, Joyce Fang, Michael J. McPherson, W. Blaine Stine, Andrew J. McCluskey · 2022 · mAbs
17. Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
    Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng‐Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter, Andreas Baumann · 2022 · mAbs
18. Towardin vitro-to-in vivotranslation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms
    Claudia A. Castro Jaramillo, Sara Belli, Anne‐Christine Cascais, Sherri Dudal, Martin R. Edelmann, Markus Haak, Marie-Elise Brun, Michael B. Otteneder, Mohammed Ullah, Christoph Funk et al. · 2017 · mAbs
19. Current challenges and opportunities in nonclinical safety testing of biologics
    Sven Kronenberg, Andreas Baumann, Lolke de Haan, Heather J. Hinton, Jonathan G. Moggs, Frank‐Peter Theil, Ian D. Wakefield, Thomas Singer · 2013 · Drug Discovery Today
20. Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody
    Jing Dai, Saeed Izadi, Jonathan Zarzar, Patrick Wu, Angela Oh, Paul J. Carter · 2024 · mAbs
21. Silica microparticles for sustained zero-order release of an anti-CD40L antibody
    Puneet Tyagi, Mika Koskinen, Jari H. Mikkola, Lasse Leino, Alexander Schwarz · 2017 · Drug Delivery and Translational Research
22. Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys
    Lise I. Loberg, Meha Chhaya, Alexander R. Ibraghimov, Edit Tarcsa, Andreas Striebinger, Andreas Popp, Lili Huang, Frank Oellien, Stefan Barghorn · 2021 · mAbs
23. Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies
    Andrew B. Dippel, Austin S. Gallegos, Vineela Aleti, Arnita S. Barnes, Xiaoru Chen, Elizabeth A. Christian, Jared A. Delmar, Qun Du, Reza Esfandiary, Erika Farmer et al. · 2022 · mAbs
24. Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity
    Catherine Y. Liu, Cory L. Ahonen, Michael E. Brown, Ling Hui Zhou, Martin Welin, Eric M. Krauland, Robert Pejchal, Paul Widboom, Michael B. Battles · 2023 · mAbs
25. A specialized integrin-binding motif enables proTGF-β2 activation by integrin αVβ6 but not αVβ8
    Viet Q. Le, Bo Zhao, Siddanth Ramesh, Cameron Toohey, Adam DeCosta, Julian Mintseris, Xinyue Liu, Steven P. Gygi, Timothy A. Springer · 2023 · Proceedings of the National Academy of Sciences
26. Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions
    Hsin-Ting Chen, Yulei Zhang, Jie Huang, Manali S. Sawant, Matthew D. Smith, Nandhini Rajagopal, Alec A. Desai, Emily K. Makowski, Giuseppe Licari, Yunxuan Xie et al. · 2024 · Cell Reports
27. Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities
    Maxime Lecerf, Alexia Kanyavuz, Sofia Rossini, Jordan D. Dimitrov · 2021 · Communications Biology
28. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies
    Shufang Liu, Dhaval K. Shah · 2023 · The AAPS Journal
29. Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows
    Tushar S. Jain, Bianka Prinz, Alexander Marker, Alexander Michel, Katrin Reichel, Valérie Czepczor, Sylvie Klieber, Wei Sun, Sagar V. Kathuria, Sevim Oezguer Bruederle et al. · 2024 · mAbs
30. Defining and Studying B Cell Receptor and TCR Interactions
    C. Garrett Rappazzo, Monica L. Fernández‐Quintero, Andreas Mayer, Nicholas C. Wu, Victor Greiff, Jenna J. Guthmiller · 2023 · The Journal of Immunology
31. 177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer
    Evangelia-Alexandra Salvanou, Argiris Kolokithas Ntoukas, Danai E. Prokopiou, Maria Theodosiou, Eleni Κ. Efthimiadou, Przemysław Koźmiński, Stavros Xanthopoulos, Konstantinos Avgoustakis, Penelope Bouziotis · 2024 · Molecules
32. Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning
    Patrick S. Koenig, Sarah Sanowar, Chingwei V. Lee, Germaine Fuh · 2017 · mAbs
33. Engineering broadly neutralizing antibodies for HIV prevention and therapy
    Casey K. Hua, Margaret E. Ackerman · 2016 · Advanced Drug Delivery Reviews
34. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
    Josefa Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang et al. · 2020 · mAbs
35. Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations
    Kenta Haraya, Tatsuhiko Tachibana · 2022 · BioDrugs
36. An automated immunoassay for early specificity profiling of antibodies
    Katrin Frese, Meike Eisenmann, Ralf Ostendorp, Bodo Brocks, Stefan Pabst · 2013 · mAbs
37. Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
    Adonis A. Rubio, Viren A. Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E. Abernathy, Zijun Wang, Yu Erica Lee, Michael R. Eso, Jennie L. Phung, Israel Ramos et al. · 2025 · Science Translational Medicine
38. Microphysiological endothelial models to characterize subcutaneous drug absorption
    Giovanni S. Offeddu · 2022 · ALTEX
39. Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review
    Amirhossein Tamimi, Atena Tamimi, Fatemeh Sorkheh, Saba Mardekatani Asl, Arezoo Ghafari, Arian Ghannadi Karimi, Gisou Erabi, Hossein Pourmontaseri, Niloofar Deravi · 2023 · Cancer Reports
40. A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice
    Aman Mebrahtu, Ida Laurén, Rosanne E. Veerman, Gözde Güçlüler Akpinar, Martin Lord, Alexandros Kostakis, Juan Astorga‐Wells, Leif Dahllund, Anders Olsson, Oscar Andersson et al. · 2024 · Nature Communications
41. Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging
    Liang Zhang, Greg M. Thurber · 2015 · Molecular Imaging and Biology
42. Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics
    Hanine Rafidi, Alberto Estevez, Gregory Z. Ferl, Danielle Mandikian, Shannon L. Stainton, Lauren N. Sermeño, Simon Peter Williams, Amrita V. Kamath, James T. Koerber, C. Andrew Boswell · 2021 · Molecular Cancer Therapeutics
43. Incorporation of FcRn‐mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients
    Chee M. Ng · 2015 · Biopharmaceutics & Drug Disposition
44. Complex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics
    Dan Lü, Rajbharan Yadav, Patrick G. Holder, Eugene Y. Chiang, Shomyseh Sanjabi, Victor Poon, Matthew J. Bernett, Rajat Varma, Ke Liu, Irene Leung et al. · 2023 · European Journal of Pharmaceutical Sciences
45. Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies
    Xin Yu, Kostika Vangjeli, Anusha Prakash, Meha Chhaya, Samantha J Stanley, Noah D. Cohen, Lili Huang · 2024 · Antibody Therapeutics
46. Characterization and Modeling of Reversible Antibody Self-Association Provide Insights into Behavior, Prediction, and Correction
    Carl Mieczkowski, Alan C. Cheng, Thierry O. Fischmann, Mark Hsieh, Jeanne Baker, Makiko Uchida, Gopalan Raghunathan, Corey Strickland, Laurence Fayadat‐Dilman · 2021 · Antibodies
47. Stability of monoclonal antibodies after simulated subcutaneous administration
    Joachim Schuster, Hanns‐Christian Mahler, Susanne Joerg, Vinay Kamuju, Jörg Huwyler, Roman Mathaes · 2021 · Journal of Pharmaceutical Sciences
48. Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework
    Romain Ollier, Aline Fuchs, Florence Gauye, Katarzyna Piorkowska, Sébastien Menant, Monisha Ratnam, Paolo Montanari, Florence Guilhot, Didier Phillipe, Mickaël Audrain et al. · 2023 · mAbs
49. DOTAD: A Database of Therapeutic Antibody Developability
    Wenzhen Li, Hong‐Yan Lin, Ziru Huang, Shiyang Xie, Yuwei Zhou, Rong Gong, Qianhu Jiang, Changcheng Xiang, Jian Hua Huang · 2024 · Interdisciplinary Sciences Computational Life Sciences
50. Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
    Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary R. Morrow, Arthur E. Reyes, Melissa Cheu, Jessica L. Li, Jeffrey J. Wallin et al. · 2022 · Pharmaceutics
51. Prediction of polyreactive and nonspecific single-chain fragment variables through structural biochemical features and protein language-based descriptors
    Hocheol Lim, Kyoung Tai No · 2022 · BMC Bioinformatics
52. A dual host vector for Fab phage display and expression of native IgG in mammalian cells
    Devin B. Tesar, Isidro Hötzel · 2013 · Protein Engineering Design and Selection
53. Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules
    Amita Datta‐Mannan, Robin M. Brown, Stephanie Key, Paul Cain, Yiqing Feng · 2021 · Antibodies
54. PULSE SPR: A High Throughput Method to Evaluate the Domain Stability of Antibodies
    Li Zhou, Jun Zhang, Enrico L. DiGiammarino, Amol Kavishwar, Bo Yan, Chris M. Chumsae, Peter M. Ihnat, David Powers, John E. Harlan, W. Blaine Stine · 2018 · Analytical Chemistry
55. Cross‐Interaction Chromatography‐Based QSAR Model for Early‐Stage Screening to Facilitate Enhanced Developability of Monoclonal Antibody Therapeutics
    Arathi Kizhedath, Micael Karlberg, Jarka Glassey · 2019 · Biotechnology Journal
56. Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys
    Pai, Rama, Ma, Ning, Connor, Anu V., Danilenko, Dimitry M., Tarrant, Jacqueline M., Salvail, Dany, Wong, Lisa, Hartley, Dylan P., Misner, Dinah, Stefanich, Eric et al. · 2016 · Toxicological Sciences
57. Improving antibody drug development using bionanotechnology
    Emily K. Makowski, John S. Schardt, Peter M. Tessier · 2021 · Current Opinion in Biotechnology
58. The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies
    Leon F. Willis, Amit Kumar, Tushar S. Jain, Isabelle Caffry, Yingda Xu, Sheena E. Radford, Nikil Kapur, Maximiliano Vásquez, David J. Brockwell · 2020 · Engineering Reports
59. Harnessing the Therapeutic Potential of ‘Rogue’ Antibodies
    Jordan D. Dimitrov · 2020 · Trends in Pharmacological Sciences
60. High-Throughput Assay for Measuring Monoclonal Antibody Self-Association and Aggregation in Serum
    Xiaoning Li, Steven B. Geng, Mark L. Chiu, Dorina Saro, Peter M. Tessier · 2015 · Bioconjugate Chemistry
61. A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States
    Sarfaraz K. Niazi · 2023 · Healthcare
62. Support for Removing Pharmacodynamic and Clinical Efficacy Testing of Biosimilars: A Critical Analysis
    Sarfaraz K. Niazi · 2023 · Clinical Pharmacology in Drug Development
63. Preferential precipitation of acidic variants from monoclonal antibody pools
    Tomasz Rumanek, Michał Kołodziej, Wojciech Piątkowski, Dorota Antos · 2022 · Biotechnology and Bioengineering
64. SUMO: In Silico Sequence Assessment Using Multiple Optimization Parameters
    Andreas Evers, Shipra Malhotra, Wolf-Guido Bolick, Ahmad Najafian, Maria Borisovska, Shira Warszawski, Yves Fomekong‐Nanfack, Daniel Kühn, Friedrich Rippmann, Alejandro Crespo et al. · 2023 · Methods in molecular biology
65. Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys
    Amita Datta‐Mannan, Jeffrey S. Boyles, Lihua Huang, Zhiying Jin, Amber Peariso, Anthony Murphy, Bernice Ellis, Nicole E. Douglass, Fariba Norouziyan-Cooper, Derrick R. Witcher · 2018 · Biotechnology Journal
66. Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies
    Jason Robarge, Kevin M. Budge, Lucy Her, Andrea M. Patterson, Patricia Brown‐Augsburger · 2024 · Antibodies
67. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies
    Mark A. Bryniarski, Md Tariqul Haque Tuhin, Timothy M. Acker, Devin L. Wakefield, Panijaya Sethaputra, Kevin D. Cook, Marcus Soto, Manuel Ponce, Ronya Primack, Aditya Jagarapu et al. · 2024 · Journal of Pharmaceutical Sciences
68. Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining
    Yi-Chun Hsiao, Heidi Ackerly Wallweber, Robert G. Alberstein, Zhonghua Lin, Changchun Du, Ainhoa Etxeberría, Theint Aung, Yonglei Shang, Dhaya Seshasayee, Franziska Seeger et al. · 2024 · Nature Communications
69. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
    Weon Sup Lee, Sang Ryeol Shim, Seon Young Lee, Jin San Yoo, Sung Kweon Cho · 2018 · Drug Design Development and Therapy
70. The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic Antibodies
    Peter M. Bowers, William J. Boyle, Robert D. Damoiseaux · 2018 · Methods in molecular biology
71. Restricted epitope specificity determined by variable region germline segment pairing in rodent antibody repertoires
    Yi-Chun Hsiao, Ying-Jiun J. Chen, Leonard D. Goldstein, Jia Wu, Zhonghua Lin, Kellen Schneider, Subhra Chaudhuri, Aju Antony, Kanika Bajaj Pahuja, Zora D. Modrusan et al. · 2020 · mAbs
72. A Cell-Based FcRn-dependent Recycling assay for Predictive Pharmacokinetic assessment of Therapeutic Antibodies
    Liu, Chang, Kim, Yeon Su, Lowe, John Hok-Nin, Chung, Shan · 2021 · Bioanalysis
73. Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy
    Rajbharan Yadav, Suzanne Schubbert, Patrick G. Holder, Eugene Y. Chiang, Nargess Hassanzadeh‐Kiabi, Liz Bogaert, Irene Leung, Rumana Rashid, Kendra N. Avery, Christine Bonzon et al. · 2024 · Frontiers in Pharmacology
74. Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies
    Mark A. Bryniarski, Md Tariqul Haque Tuhin, Carolyn D. Shomin, Fatemeh Nasrollahi, Eunkyung Clare Ko, Marcus Soto, Kyu Chung, Carrie Poon-Andersen, Ronya Primack, Diana Wong et al. · 2024 · Journal of Pharmaceutical Sciences
75. Balancing the Affinity and Pharmacokinetics of Antibodies by Modulating the Size of Charge Patches on Complementarity-Determining Regions
    Yue Sun, Hao Cai, Zhilan Hu, C. Andrew Boswell, Jinpian Diao, Charlene Li, Liangyi Zhang, Amy Y. Shen, Christopher A. Teske, Boyan Zhang et al. · 2020 · Journal of Pharmaceutical Sciences
76. Identification of polyreactive antibodies by high throughput enzyme-linked immunosorbent assay and surface Plasmon resonance
    Luis Antonio Rodriguez Carnero, Daniel Bedinger, Simon Cocklin, Jianquan Li, M. Frank Erasmus, Sara D’Angelo, Camila Leal‐Lopes, Andre A. R. Teixeira, Fortunato Ferrara, Andrew M. Bradbury · 2025 · Journal of Immunological Methods
77. 89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice
    Linda N. Broer, Daan G. Knapen, Frans V. Suurs, Ingrid Nyhus Moen, Danique Giesen, Stijn J.H. Waaijer, Baard Indrevoll, Christine Ellingsen, Alexander Kristian, Alan Cuthbertson et al. · 2022 · Journal of Nuclear Medicine
78. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
    Shufang Liu, Sara C. Humphreys, Kevin D. Cook, Kip P. Conner, Ana R. Correia, Alex W. Jacobitz, Melissa Yang, Ronya Primack, Marcus Soto, Rupa Padaki et al. · 2023 · mAbs
79. Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
    Abhay Kumar Singh, Calvin D. Lewis, Cristian A.W.V. Boas, Philipp Diebolder, Prashant N. Jethva, Aaron J. Rhee, Jong Hee Song, Young Ah Goo, Shunqian Li, Michael L. Nickels et al. · 2024 · Clinical Cancer Research
80. Protein Stability After Administration: A Physiologic Consideration
    Joachim Schuster, Vinay Kamuju, Roman Mathaes · 2022 · Journal of Pharmaceutical Sciences
81. Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases
    Rajbharan Yadav, Siddharth Sukumaran, Jeff Lutman, Mayur S. Mitra, Wendy Halpern, Tianhe Sun, Audi Setiadi, Margaret Neighbors, X. Rebecca Sheng, Victor Yip et al. · 2023 · Journal of Pharmaceutical Sciences
82. Membrane Proteins as Targets for Biological Drugs
    Vanita D. Sood, Alec W. Gross · 2019 · Springer eBooks
83. Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells
    Yuki Noguchi, Kazuhisa Ozeki, Hidetaka Akita · 2020 · Scientific Reports
84. Generation of mAb Variants with Less Attractive Self-Interaction but Preserved Target Binding by Well-Directed Mutation
    Martin Domnowski, Ken Lo Presti, Jonas Binder, Josef Reindl, Lucille Lehmann, Felix Kummer, Meike Wolber, Marion Satzger, Marco Dehling, Jan Jaehrling et al. · 2020 · Molecular Pharmaceutics
85. Antibody Engineering and Therapeutics
    Juan Carlos Almagro, Gary L. Gilliland, Felix J. Breden, Jamie Kathleen Scott, Devin Sok, Matthias G. Pauthner, Janice M. Reichert, Gustavo F. Helguera, Raiees Andrabi, Robert Mabry et al. · 2014 · mAbs
86. Does one model fit all mAbs? An evaluation of population pharmacokinetic models
    Stefan P. H. van den Berg, Philine E. A. Adolfsen, Thomas P. C. Dorlo, Theo Rispens · 2025 · mAbs
87. Enhanced rational protein engineering to reduce viscosity in high-concentration IgG1 antibody solutions
    Tyler J. Lefevre, Jenna G Caldwell, Austin S. Gallegos, Qun Du, Erin Houston, Gilad Kaplan, Reza Esfandiary · 2025 · mAbs
88. Predicting the Pharmacokinetics of T‐Cell Engagers as a Function of Target‐Mediated Drug Disposition
    Mark Penney, Alberto Ippolito, Elisa Fevola, Scott Rata, Liam Brown, Pablo Morentin Gutierrez, Rhys D. O. Jones · 2025 · Clinical and Translational Science
89. Reinventing Therapeutic Proteins: Mining a Treasure of New Therapies
    Sarfaraz K. Niazi, Zamara Mariam · 2023 · Biologics
90. A role for macromolecular crowding in off-target binding of therapeutic antibodies
    M Klinger · 2017 · Protein Engineering Design and Selection
91. Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey
    Kenta Haraya, Tatsuhiko Tachibana, Jun‐ichi Nezu · 2016 · Xenobiotica
92. Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody
    Sharon M. Campbell, Joseph DeBartolo, James R. Apgar, Lydia Mosyak, Virginie McManus, Sonia Beyer, Eric M. Bennett, Matthew A. Lambert, Orla Cunningham · 2021 · mAbs
93. Leveraging protein language and structural models for early prediction of antibodies with fast clearance
    Parisa Mazrooei, Daniel O’Neil, Saeed Izadi, Bingyuan Chen, Saroja Ramanujan · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
94. Drug-like antibody design against challenging targets with atomic precision
    Chai Discovery Team, Jacques Boitreaud, Robert S. Chen, Jack Dent, Lucy Fairweather, Danny Geisz, Matthew Greenig, Nate Boyd, Jinay Jain, Brady Johnston et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
95. 23ME-01473, an Fc Effector–Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell–Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation
    Joel S. Benjamin, Abigail P Jarret, Shashank Bharill, Pierre Fontanillas, Shruti Yadav, Debasish Sen, Dina A. Ayupova, Danielle Kellar, Susanne Tilk, Clifford Hom et al. · 2025 · Cancer Research Communications
96. Countercurrent preferential precipitation of acidic variants from monoclonal antibody pools
    Tomasz Rumanek, Michał Kołodziej, Wojciech Piątkowski, Dorota Antos · 2024 · Process Safety and Environmental Protection
97. Molecular Assessment of Monoclonal Antibody-Based Therapeutics Enabling Lead Selection for Clinical Development
    Vikas Kumar Sharma, Robert F. Kelley · 2015 · AAPS advances in the pharmaceutical sciences series
98. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    I. Burvenich, W. Farrugia, Zhan-Qi Liu, Dahna Makris, D. King, Benjamin Gloria, A. Perani, Laura Allan, A. Scott, P. Ramsland · 2018 · Biochemical Journal
99. Interaction with 2,4-dinitrophenol correlates with polyreactivity, self-binding, and stability of clinical-stage therapeutic antibodies
    Valentin Dietlin-Auril, Maxime Lecerf, Stephanie Depinay, Rémi Noé, Jordan D. Dimitrov · 2021 · Molecular Immunology
100. Complex formation of anti‐VEGF‐C with VEGF‐C released during blood coagulation resulted in an artifact in its serum pharmacokinetics
     Daniela Bumbaca Yadav, Arthur E. Reyes, Priyanka Gupta, Jean-Michel Vernes, Y. Gloria Meng, Michelle G. Schweiger, Shannon L. Stainton, Germaine Fuh, Paul J. Fielder, Amrita V. Kamath et al. · 2020 · Pharmacology Research & Perspectives